Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16576851 | 0.83 | CYP11B2 (0.31) | CYP11B2 | |
| SCHEMBL29954823 | 0.81 | — | — | |
| SCHEMBL1192318 | 0.78 | VRK1 (0.32) | — | |
| SCHEMBL2714951 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL26963672 | 0.78 | — | — | |
| SCHEMBL29514284 | 0.78 | VRK1 (0.32) | — | |
| SCHEMBL29951515 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL29956471 | 0.77 | UHRF1 (0.35) | — | |
| SCHEMBL15051004 | 0.77 | CYP3A4 (0.34) | — | |
| SCHEMBL29911719 | 0.77 | CYP3A4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149941-B1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | ALGEN BIOTECHNOLOGIES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-116261561-A | Certain chemical compositions and methods of use thereof | 奧基生物技术有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023086417-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086417-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ALGEN BIOTECHNOLOGIES, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4149941-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | Algen Biotechnologies, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | NOVARTIS AG (CH) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012661-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| EP-2125793-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
| EP-2125793-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | Eli Lilly & Company (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008076704-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT' OF CANCER | ELI LILLY AND COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, BUB1B, BUB1 | GPBAR1 3999/4885CYP11B2 4551/4885MKNK1 125/4885 |
| US-20110028492-A1 | Heteroaryl Compounds and Their Uses | CDK9, CDK19, CDK3 | GPBAR1 990/4885CYP11B2 223/4885MKNK1 314/4885 |
| US-20230295135-A1 | CERTAIN CHEMICAL COMPOSITIONS AND METHODS OF USE THEREOF | CDK9, CDK19, CDK6 | GPBAR1 1948/4885CYP11B2 1232/4885MKNK1 484/4885 |
| US-12264152-B2 | Certain chemical compositions and methods of use thereof | CDK9, CDK19, CDK6 | GPBAR1 1948/4885CYP11B2 1232/4885MKNK1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.